{
  "source": "PA-Notification-Xphozah.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1427-2\nProgram Prior Authorization/Notification\nMedication Xphozah® (tenapanor)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nXphozah® (tenapanor) is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce\nserum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in\npatients who have an inadequate response to phosphate binders or who are intolerant of any dose\nof phosphate binder therapy.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Xphozah will be approved based on all of the following criteria:\na. Diagnosis of chronic kidney disease (CKD)\n-AND-\nb. Patient is receiving dialysis\n-AND-\nc. Xphozah will be used as add-on therapy to reduce serum phosphorus\n-AND-\nd. One of the following:\n(1) Patient has had an inadequate response to phosphate binder therapy [e.g., calcium\nacetate, sevelamer, lanthanum, Velphoro (sucroferric oxyhydroxide)]\n-OR-\n(2) Patient is intolerant to any dose of phosphate binder therapy\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Xphozah will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Documentation of positive clinical response to Xphozah therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Xphozah® [package insert]. Waltham, MA: Ardelyx, Inc.; October 2023.\nProgram Prior Authorization/Notification - Xphozah (",
    "proval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Xphozah® [package insert]. Waltham, MA: Ardelyx, Inc.; October 2023.\nProgram Prior Authorization/Notification - Xphozah (tenapanor)\nChange Control\n1/2024 New program.\n1/2025 Annual review with no updates.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}